Mersana Therapeutics, Inc. (MRSN)

Recent filings

Mersana Therapeutics Reports Updated Data From The Xmt-1536 Phase 1 Dose Escalation Study - March 30, 2020

Mersana Therapeutics To Report Updated Data From The Xmt-1536 Phase 1 Dose Escalation Study - March 20, 2020

Confidential treatment order - March 17, 2020

Entry into a Material Definitive - March 16, 2020

Mersana Therapeutics, Inc. Just Filed Its Annual Report: Net Loss per Shar... - Feb. 28, 2020

Mersana Therapeutics Announces Fourth Quarter And Full Year 2019 Financial Results And Provides Business Updates - Feb. 28, 2020

Mark N. Lampert just provided an update on share ownership of Mersana Therapeutics, Inc. - Feb. 14, 2020

ArrowMark Colorado Holdings, LLC just issued a filing suggesting it has sold all of its Mersana Therapeutics, Inc. - Feb. 14, 2020

BlackRock, Inc. just provided an update on share ownership of Mersana Therapeutics, Inc. - Feb. 7, 2020

VP of Mersana Therapeutics, Inc. was just granted 18,333 options and restricted shares - Jan. 16, 2020

Chief Bus. Officer of Mersana Therapeutics, Inc. was just granted 100,833 options and restricted shares - Jan. 16, 2020

Sr. of Mersana Therapeutics, Inc. was just granted 146,667 options and restricted shares - Jan. 16, 2020

Sr. VP. of Mersana Therapeutics, Inc. was just granted 87,083 options and restricted shares - Jan. 16, 2020

Mersana Therapeutics, Inc.'s Chief Medical Officer was just granted 100,833 options and restricted shares - Jan. 16, 2020

Mersana Therapeutics, Inc.'s President & CEO was just granted 389,583 options and restricted shares - Jan. 16, 2020

Chief Science of Mersana Therapeutics, Inc. was just granted 174,167 options and restricted shares - Jan. 16, 2020

Mersana Therapeutics: Accelerating Adc Innovation …Because Patients Are Waiting January 2020 - Jan. 10, 2020

Mersana Therapeutics, Inc. director was just granted 11,264 options - Jan. 3, 2020

Major owner of Mersana Therapeutics, Inc. was just granted 19,713 options - Jan. 3, 2020

Mersana Therapeutics, Inc. director was just granted 11,264 options - Jan. 3, 2020

Mersana Therapeutics, Inc. director was just granted 11,264 options - Jan. 3, 2020

Koh, Bong just provided an update on share ownership of Mersana Therapeutics, Inc. - Dec. 23, 2019

Entry into a Material Definitive - Nov. 27, 2019

Mersana Therapeutics, Inc. Just Filed Its Quarterly Report: Net Loss per Shar... - Nov. 6, 2019

Mersana Therapeutics Announces Third Quarter 2019 Financial Results And Provides Business Updates - Nov. 6, 2019

Mark N. Lampert just provided an update on share ownership of Mersana Therapeutics, Inc. - Oct. 9, 2019

Mersana Therapeutics Announces Initiation Of Expansion Study Of Xmt-1536 In Patients With Platinum-Resistant Ovarian Cancer And Non-Small Cell Lung Cancer (Nsclc) Adenocarcinoma - Aug. 21, 2019

Mersana Therapeutics, Inc. Just Filed Its Quarterly Report: 8. Earnings per s... - Aug. 8, 2019

Mersana Therapeutics Announces Second Quarter 2019 Financial Results And Provides Business Updates - Aug. 8, 2019

Departure of Directors or Certain - July 26, 2019

Mersana Therapeutics, Inc.'s Chief Scientific Officer was just granted 40,000 restricted shares - July 19, 2019

CBO of Mersana Therapeutics, Inc. was just granted 40,000 restricted shares - July 19, 2019

Mersana Therapeutics, Inc.'s President & CEO was just granted 100,000 restricted shares - July 19, 2019

Sr VP Chemistry of Mersana Therapeutics, Inc. was just granted 40,000 restricted shares - July 19, 2019

Mersana Therapeutics, Inc.'s Chief Medical Officer was just granted 40,000 restricted shares - July 19, 2019

Sr. VP of Mersana Therapeutics, Inc. was just granted 240,000 options - July 12, 2019

Sr. VP of Mersana Therapeutics, Inc. just declared ownership of no shares of Mersana Therapeutics, Inc. - July 12, 2019

Mersana Therapeutics Announces Appointment Of Brian C. Deschuytner As Senior Vice President Of Finance And Product Strategy - June 12, 2019

Major owner of Mersana Therapeutics, Inc. was just granted 25,000 options - June 11, 2019

Mersana Therapeutics, Inc. director was just granted 25,000 options - June 11, 2019

Mersana Therapeutics, Inc. director was just granted 25,000 options - June 11, 2019

Mersana Therapeutics, Inc. director was just granted 25,000 options - June 11, 2019

Mersana Therapeutics, Inc. director was just granted 25,000 options - June 11, 2019

Submission of Matters to a Vote of Security - June 7, 2019

Mersana Therapeutics: Mersana Presents Interim Phase 1 Data For Xmt-1536 At The 2019 American Society Of Clinical Oncology Annual Meeting - June 5, 2019

Mersana Therapeutics, Inc. Just Filed Its Quarterly Report: 7. Earnings per s... - May 9, 2019

Mersana Therapeutics Announces First Quarter 2019 Financial Results And Provides Business Updates - May 9, 2019

Mersana Therapeutics: Soliciting Material Under §240.14A-12 MERSANA THERAPEUTICS, INC. - April 23, 2019

Mersana Therapeutics, Inc. releases salary data. CEO sees compensation rise 184% - April 23, 2019

Annual Meeting and Record Date - April 8, 2019

Mark N. Lampert just provided an update on share ownership of Mersana Therapeutics, Inc. - March 11, 2019

Sarissa Capital Hawkeye Fund LP just provided an update on share ownership of Mersana Therapeutics, Inc. - March 11, 2019

Securities to be offered to employees in employee benefit plans - March 8, 2019

Mersana Therapeutics, Inc. Just Filed Its Annual Report: Net Loss per Shar... - March 8, 2019

Mersana Therapeutics Announces Fourth Quarter And Full Year 2018 Financial Results And Provides Business Updates - March 8, 2019

Major owner of Mersana Therapeutics, Inc. just picked up 3,750,000 shares - March 6, 2019

Major owner of Mersana Therapeutics, Inc. just picked up 3,750,000 shares - March 6, 2019

Mersana Therapeutics, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - March 4, 2019

Mersana Therapeutics: Information Relating To Part Ii - March 4, 2019

Mersana Therapeutics, Inc. just filed a prospectus, suggesting it plans to soon issue some securities - Feb. 28, 2019

Mersana Therapeutics: Unleashing The Targeted Power Of Adcs February 2019 - Feb. 28, 2019

Rock Springs Capital Master Fund LP just provided an update on share ownership of Mersana Therapeutics, Inc. - Feb. 14, 2019

ArrowMark Colorado Holdings, LLC just provided an update on share ownership of Mersana Therapeutics, Inc. - Feb. 14, 2019

ArrowMark Colorado Holdings, LLC just provided an update on share ownership of Mersana Therapeutics, Inc. - Feb. 14, 2019

Mersana Therapeutics, Inc.'s Chief Financial Officer was just granted 100,000 options - Jan. 25, 2019

Mersana Therapeutics, Inc.'s Chief Scientific Officer was just granted 60,000 options - Jan. 25, 2019

Sr VP Chemistry of Mersana Therapeutics, Inc. was just granted 60,000 options - Jan. 25, 2019

Mersana Therapeutics, Inc.'s Vice President of Finance was just granted 30,750 options - Jan. 25, 2019

Mersana Therapeutics, Inc.'s President & CEO was just granted 217,500 options - Jan. 25, 2019

CBO of Mersana Therapeutics, Inc. was just granted 60,000 options - Jan. 25, 2019

Wellington Investment Advisors Holdings LLP just provided an update on share ownership of Mersana Therapeutics, Inc. - Jan. 10, 2019

Termination of a Material Definitive - Jan. 4, 2019

Mersana Therapeutics, Inc. director was just granted 13,619 options - Jan. 4, 2019

Mersana Therapeutics, Inc. director was just granted 13,619 options - Jan. 4, 2019

Major owner of Mersana Therapeutics, Inc. was just granted 25,292 options - Jan. 4, 2019

Mersana Therapeutics Announces Strategic Priorities And Goals For 2019 And Beyond - Jan. 4, 2019

Mersana Therapeutics, Inc.'s Chief Medical Officer was just granted 100,000 options - Dec. 3, 2018

Mersana Therapeutics, Inc.'s Chief Medical Officer just declared ownership of no shares of Mersana Therapeutics, Inc. - Dec. 3, 2018

Mersana Therapeutics Announces Third Quarter 2018 Financial Results And Provides Business Updates - Nov. 13, 2018

Mersana Therapeutics, Inc.'s Chief Scientific Officer just cashed-in 3,500 options - Sept. 25, 2018

Major owner of Mersana Therapeutics, Inc. was just granted 10,000 options - Sept. 21, 2018

Mersana Therapeutics, Inc. director was just granted 10,000 options - Sept. 21, 2018

Mersana Therapeutics, Inc. director was just granted 10,000 options - Sept. 21, 2018

Mersana Therapeutics, Inc. director was just granted 10,000 options - Sept. 21, 2018

Mersana Therapeutics, Inc. Just Received a Notice of Effectiveness - Sept. 17, 2018

Registration statement under Securities Act of 1933 - Sept. 14, 2018

Mersana Therapeutics, Inc.'s Chief Scientific Officer just cashed-in 3,500 options - Aug. 29, 2018

Mersana Therapeutics, Inc.'s Chief Scientific Officer just disposed of 3,500 shares - July 25, 2018

Mersana Therapeutics Announces Partial Clinical Hold For Xmt-1522 Clinical Trial - July 23, 2018

Registration statement under Securities Act of 1933 - July 12, 2018

Mersana Therapeutics, Inc.'s Chief Scientific Officer just picked up 10,000 shares - July 5, 2018

Registration statement under Securities Act of 1933 - July 2, 2018

Submission of Matters to a Vote of Security - June 29, 2018

Mersana Therapeutics: Soliciting Material Under §240.14A-12 MERSANA THERAPEUTICS, INC. - June 11, 2018

Mersana Therapeutics, Inc. Just Filed Its Quarterly Report: Net Loss per Shar... - May 15, 2018

Mersana Therapeutics, Inc. releases salary data. CEO sees compensation fall -9% - April 30, 2018

Departure of Directors or Certain - April 10, 2018

Mersana Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results And Provides Business Updates - March 28, 2018

Mersana Therapeutics, Inc. Just Filed Its Annual Report: Net Loss per Shar... - March 28, 2018

Mersana Therapeutics, Inc. director was just granted 20,000 options - March 21, 2018

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. NEA Management Company, LLC 11,963,649 3.3 Dec. 31, 2019
2. Sarissa Capital Management LP 3,750,000 0.7 Sept. 30, 2019
3. ORBIMED ADVISORS LLC 2,073,319 0.2 Dec. 31, 2019
4. VANGUARD GROUP INC 1,903,502 N/A June 30, 2019
5. Boxer Capital, LLC 1,680,800 0.2 Sept. 30, 2019
6. Rock Springs Capital Management LP 1,233,000 0.2 Dec. 31, 2019
7. BVF INC/IL 1,180,553 0.5 Dec. 31, 2019
8. ProQuest Associates IV LLC 955,709 22.5 June 30, 2017
9. VHCP Management II, LLC 922,514 1.5 Dec. 31, 2019
10. WELLINGTON MANAGEMENT CO LLP 867,916 N/A Sept. 30, 2019
11. WELLINGTON MANAGEMENT CO LLP 867,916 N/A Sept. 30, 2019
12. MILLENNIUM MANAGEMENT LLC 803,541 N/A Dec. 31, 2019
13. Ghost Tree Capital, LLC 800,000 0.8 Dec. 31, 2019
14. RHO CAPITAL PARTNERS INC 796,458 3.5 Dec. 31, 2019
15. RENAISSANCE TECHNOLOGIES LLC 719,768 N/A Dec. 31, 2019
16. State Street Corp 620,685 N/A Dec. 31, 2019
17. Point72 Asset Management, L.P. 495,000 N/A Sept. 30, 2019
18. GEODE CAPITAL MANAGEMENT, LLC 484,412 N/A Sept. 30, 2019
19. JPMORGAN CHASE & CO 335,350 N/A Sept. 30, 2017
20. FMR LLC 256,328 N/A Dec. 31, 2019
21. D. E. Shaw & Co., Inc. 244,816 N/A June 30, 2019
22. Citadel Advisors LLC 220,102 N/A Dec. 31, 2019
23. NORTHERN TRUST CORP 180,068 N/A March 31, 2019
24. Sio Capital Management, LLC 166,250 0.2 Dec. 31, 2019
25. BRIDGEWAY CAPITAL MANAGEMENT INC 159,400 N/A Dec. 31, 2019
26. D. E. Shaw & Co., Inc. 148,147 N/A Dec. 31, 2019
27. ACADIAN ASSET MANAGEMENT LLC 129,596 N/A Dec. 31, 2019
28. PANAGORA ASSET MANAGEMENT INC 124,158 N/A Dec. 31, 2019
29. NORTHERN TRUST CORP 111,669 N/A March 31, 2018
30. DAFNA Capital Management LLC 108,463 0.2 Dec. 31, 2019

Mersana Therapeutics, Inc. (MRSN)

140

cctranscripts

March 30, 2020

Mersana Therapeutics Reports Updated Data From The Xmt-1536 Phase 1 Dose Escalation Study http://www.conferencecalltranscripts.org/pink/summary?id=7673155

cctranscripts

March 20, 2020

Mersana Therapeutics To Report Updated Data From The Xmt-1536 Phase 1 Dose Escalation Study http://www.conferencecalltranscripts.org/pink/summary?id=7625597

cctranscripts

March 17, 2020

Confidential treatment order http://www.conferencecalltranscripts.org/pink/summary?id=7604229

cctranscripts

March 16, 2020

Entry into a Material Definitive http://www.conferencecalltranscripts.org/pink/summary?id=7596552

cctranscripts

Feb. 28, 2020

Mersana Therapeutics, Inc. Just Filed Its Annual Report: Net Loss per Shar... http://www.conferencecalltranscripts.org/pink/summary?id=7513720

cctranscripts

Feb. 28, 2020

Mersana Therapeutics Announces Fourth Quarter And Full Year 2019 Financial Results And Provides Business Updates http://www.conferencecalltranscripts.org/pink/summary?id=7512402

cctranscripts

Feb. 14, 2020

Mark N. Lampert just provided an update on share ownership of Mersana Therapeutics, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=7442929

cctranscripts

Feb. 14, 2020

ArrowMark Colorado Holdings, LLC just issued a filing suggesting it has sold all of its Mersana Therapeutics, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=7445215

cctranscripts

Feb. 7, 2020

BlackRock, Inc. just provided an update on share ownership of Mersana Therapeutics, Inc. http://www.conferencecalltranscripts.org/pink/summary?id=7391568

cctranscripts

Jan. 16, 2020

Mersana Therapeutics, Inc.'s Chief Medical Officer was just granted 100,833 options and restricted shares http://www.conferencecalltranscripts.org/pink/summary?id=7297729

cctranscripts

Jan. 16, 2020

Sr. VP. of Mersana Therapeutics, Inc. was just granted 87,083 options and restricted shares http://www.conferencecalltranscripts.org/pink/summary?id=7297732

cctranscripts

Jan. 16, 2020

Sr. of Mersana Therapeutics, Inc. was just granted 146,667 options and restricted shares http://www.conferencecalltranscripts.org/pink/summary?id=7297712

cctranscripts

Jan. 16, 2020

VP of Mersana Therapeutics, Inc. was just granted 18,333 options and restricted shares http://www.conferencecalltranscripts.org/pink/summary?id=7297721

cctranscripts

Jan. 16, 2020

Mersana Therapeutics, Inc.'s President & CEO was just granted 389,583 options and restricted shares http://www.conferencecalltranscripts.org/pink/summary?id=7297728

cctranscripts

Jan. 16, 2020

Chief Science of Mersana Therapeutics, Inc. was just granted 174,167 options and restricted shares http://www.conferencecalltranscripts.org/pink/summary?id=7297727

cctranscripts

Jan. 16, 2020

Chief Bus. Officer of Mersana Therapeutics, Inc. was just granted 100,833 options and restricted shares http://www.conferencecalltranscripts.org/pink/summary?id=7297714

cctranscripts

Jan. 10, 2020

Mersana Therapeutics: Accelerating Adc Innovation …Because Patients Are Waiting January 2020 http://www.conferencecalltranscripts.org/pink/summary?id=7275369

cctranscripts

Jan. 3, 2020

Mersana Therapeutics, Inc. director was just granted 11,264 options http://www.conferencecalltranscripts.org/pink/summary?id=7250080

cctranscripts

Jan. 3, 2020

Major owner of Mersana Therapeutics, Inc. was just granted 19,713 options http://www.conferencecalltranscripts.org/pink/summary?id=7250214

cctranscripts

Jan. 3, 2020

Mersana Therapeutics, Inc. director was just granted 11,264 options http://www.conferencecalltranscripts.org/pink/summary?id=7250091
 


Feedback